GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

By Helena Smolak

GSK will acquire liver-disease treatment efimosfermin from Boston Pharmaceuticals for up to $2 billion to expand its portfolio.

The British pharma giant said Wednesday that it will pay the U.S. biotech company $1.2 billion up-front, and that the deal includes potential success-based milestone payments of $800 million.

Under the terms of the agreement, GSK will acquire Boston Pharmaceuticals' subsidiary BP Asset IX to access the steatotic liver-disease drug candidate.

GSK said the treatment is currently in late-stage trials and could potentially go to market in 2029. Midstage results have demonstrated the potential to reverse liver fibrosis and to stop its disease progression, it said.

Write to Helena Smolak at [e-mail]

(END) Dow Jones Newswires

05-14-25 0239ET